High doses of mineralocorticoid receptor antagonists (MRAs: spironolactone, eplerenone, and finerenone) are recommended in HF due to their well-proven effects on hard outcomes (i.e., mortality and HF hospitalizations). The gene discussed is NR3C2; the disease is hydrops fetalis.